Ceritinib
Brand names: Zykadia · Active ingredient: Ceritinib
In short: ZYKADIA® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test .
What is Ceritinib used for?
ZYKADIA® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test .
Ceritinib dosage
Select patients for treatment of metastatic NSCLC with ZYKADIA based on the presence of ALK positivity in tumor specimens .
Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.
The recommended dosage of ZYKADIA is 450 mg orally once daily with food until disease progression or unacceptable toxicity
.
If a dose of ZYKADIA is missed, make up that dose unless the next dose is due within 12 hours.
If vomiting occurs during the course of treatment, do not administer an additional dose and continue with the next scheduled dose of ZYKADIA.
Dose Reduction | Recommended Dosage
First-dose reduction | 300 mg taken orally once daily with food
Second-dose reduction | 150 mg taken orally once daily with food
Discontinue ZYKADIA for patients unable to tolerate 150 mg taken orally once daily with food.
Dosage modifications for selected adverse reactions of ZYKADIA are provided in Table 2. If dose reduction is required due to an adverse reaction not listed in Table 2, then reduce the daily dose of ZYKADIA by 150 mg.
Adverse Reaction | ZYKADIA
Dose Modification
Gastrointestinal Adverse Reactions
Severe or intolerable nausea, vomiting, or diarrhea despite optimal antiemetic or anti-diarrheal therapy | Withhold until improved, then resume ZYKADIA at the next lower dosage.
Hepatotoxicity
ALT or AST elevation greater than 5 times ULN with total bilirubin elevation less than or equal to 2 times ULN | Withhold until recovery to baseline or less than or equal to 3 times ULN, then resume ZYKADIA at the next lower dosage.
ALT or AST elevation greater than 3 times ULN with total bilirubin elevation greater than 2 times ULN in the absence of cholestasis or hemolysis | Permanently discontinue ZYKADIA.
Interstitial Lung Disease/Pneumonitis
Any Grade treatment-related ILD/pneumonitis | Permanently discontinue ZYKADIA.
QT Interval Prolongation
QTc interval greater than 500 msec on at least 2 separate ECGs | Withhold until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then resume ZYKADIA at the next lower dosage.
QTc interval prolongation in combination with torsades de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia | Permanently discontinue ZYKADIA.
Hyperglycemia
Persistent hyperglycemia greater than 250 mg/dL despite optimal anti-hyperglycemic therapy | Withhold until hyperglycemia is adequately controlled, then resume ZYKADIA at the next lower dosage.If adequate hyperglycemic control cannot be achieved with optimal medical management, discontinue ZYKADIA. …
How to take Ceritinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Gastrointestinal Adverse Reactions
Inform patients that diarrhea, nausea, vomiting, and abdominal pain are the most commonly reported gastrointestinal adverse reactions. Inform patients of supportive care options, such as antiemetic and anti-diarrheal medications. Advise patients to contact their healthcare provider for severe or intolerable gastrointestinal symptoms. Inform patients that if vomiting occurs during the course of treatment, they should not take an additional dose, but should continue with the next scheduled dose of ZYKADIA .
Hepatotoxicity
Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity .
Interstitial Lung Disease/Pneumonitis
Inform patients of the risks of severe or fatal ILD/pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms .
Arrhythmias
Inform patients of the risks of QTc interval prolongation and bradycardia. …
Warnings & precautions
Do not take this medicine if: None.
Severe gastrointestinal adverse reactions occurred in patients treated with ZYKADIA 750 mg under fasted conditions . Diarrhea, nausea, vomiting, or abdominal pain occurred in 95% of 925 patients, including severe cases (Grade 3 or 4) in 14% of patients treated with ZYKADIA across clinical studies. Diarrhea, nausea, vomiting, or abdominal pain leading to dose interruptions or reductions occurred in 36% of patients and leading to treatment discontinuation occurred in 1.6% of patients.
The incidence and severity of gastrointestinal adverse reactions were reduced for patients treated with ZYKADIA 450 mg with food in a dose optimization study (ASCEND-8). Diarrhea, nausea, vomiting, or abdominal pain occurred in 79% of 108 patients treated with ZYKADIA at the recommended dose of 450 mg with food. Of these, 53% were Grade 1 events and 24% were Grade 2 events. One patient (0.9%) experienced Grade 3 diarrhea, and one patient (0.9%) experienced Grade 3 vomiting. One patient (0.9%) required dose adjustment due to vomiting. Eleven (10%) patients had diarrhea, nausea, vomiting, or abdominal pain that required at least one dose interruption.
Monitor and manage patients using standard of care, including antidiarrheals, antiemetics, or fluid replacement, as indicated. Withhold ZYKADIA if gastrointestinal adverse reaction is severe or intolerable and is not responsive to antiemetics or antidiarrheals. Upon improvement, resume ZYKADIA at a reduced dose .
Drug-induced hepatotoxicity occurred in patients treated with ZYKADIA . Elevations in alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN) occurred in 28% and elevations in aspartate aminotransferase (AST) > 5 times ULN occurred in 16% of 925 patients across clinical studies. …
Ceritinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Gastrointestinal Adverse Reactions
Hepatotoxicity
Interstitial Lung Disease/Pneumonitis
QT Interval Prolongation
Hyperglycemia
Bradycardia
Pancreatitis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data in the Warnings and Precautions section reflect exposure to ZYKADIA 750 mg once daily under fasted conditions in 925 patients with ALK-positive NSCLC across seven clinical studies, including ASCEND-4 and ASCEND-1, described below, a randomized active-controlled study, two single arm studies, and two dose-escalation studies. The majority of patients enrolled in these studies had received prior treatment with chemotherapy and/or crizotinib for NSCLC. Among these 925 patients, the most common adverse reactions (≥ 25% incidence) were diarrhea, nausea, vomiting, fatigue, abdominal pain, decreased appetite, and weight loss. Approximately 45% of patients initiating treatment with ZYKADIA 750 mg under fasted conditions had an adverse reaction that required at least one dose reduction and 66% of patients had an adverse reaction that required at least one dose interruption. The median time to first dose reduction due to any reason was 7 weeks. …
Drug interactions
Strong CYP3A Inhibitors
A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib , which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose .
Do not consume grapefruit and grapefruit juice as they may inhibit CYP3A.
Strong CYP3A Inducers
A strong CYP3A4/P-gp inducer (rifampin) decreased the systemic exposure of ceritinib , which may decrease the efficacy of ZYKADIA. Avoid concurrent use of strong CYP3A inducers during treatment with ZYKADIA.
CYP3A Substrates
Ceritinib increased the systemic exposure of a sensitive CYP3A substrate (midazolam) . Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. If concomitant use is unavoidable, consider dose reduction of the sensitive CYP3A substrate(s). If ZYKADIA is coadministered with other CYP3A substrates, refer to the CYP3A substrate labeling for dosage recommendation with strong CYP3A inhibitors.
CYP2C9 Substrates
Ceritinib increased the systemic exposure of a CYP2C9 substrate (warfarin) . …
About this medicine
Ceritinib is a kinase inhibitor for oral administration. The molecular formula for ceritinib is C28H36N5O3ClS. The molecular weight is 558.14 g/mol. Ceritinib is described chemically as 5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine.
The chemical structure of ceritinib is shown below:
Ceritinib is a white to almost white or light yellow powder.
ZYKADIA is supplied as printed hard-gelatin capsules containing 150 mg of ceritinib and the following inactive ingredients: colloidal silicon dioxide, hard gelatin capsule shells, low substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The capsule shell is composed of FD&C Blue # 2, gelatin, and titanium dioxide.
ZYKADIA is supplied as film-coated tablets containing 150 mg of ceritinib and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose and povidone. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fff5d805-4ffd-4e8e-8e63-6f129697563e. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate